HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays

World Journal of Gastroenterology

Volumn 19, Issue 38, 2013, Pages 6438-6446

  Abrahão Machado, Lucas Faria ^a   Jácome, Alexandre Andrade dos Anjos ^b   Wohnrath, Durval Renato ^a   dos Santos, José Sebastião ^c   Carneseca, Estela Cristina ^a   Fregnani, José Humberto Tavares Guerreiro ^a   Scapulatempo Neto, Cristovam ^a  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b Materdei Hospital   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gastric cancer; Human epidermalgrowth factor receptor 2; Immunohistochemistry; Tissue microarray; Trastuzumab; Whole tissue sections

Indexed keywords

4B5 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HERCEPTEST ANTIBODY; SP3 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE AMPLIFICATION; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TISSUE MICROARRAY; TISSUE SECTION;

GASTRIC CANCER; HUMAN EPIDERMALGROWTH FACTOR RECEPTOR 2; IMMUNOHISTOCHEMISTRY; TISSUE MICROARRAY; TRASTUZUMAB; WHOLE-TISSUE SECTIONS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; AREA UNDER CURVE; BRAZIL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROTOMY; MIDDLE AGED; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; ROC CURVE; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885658744     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i38.6438     Document Type: Article

References (33)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27-39 [PMID: 15621988]
2. INCA, 2012. Available from: URL: http: //www2.inca.gov. br/wps/wcm/connect/tiposdecancer/site/home/estomago
3. Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4: 34-36 [PMID: 19454457 DOI: 10.1093/annonc/mdp122]
4. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150 [PMID: 16682732 DOI: 10.1200/JCO.2005.05.2308]
5. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646 [PMID: 3012781]
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182 [PMID: 3798106]
7. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-2209 [PMID: 10829039]
8. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65 [PMID: 20208134 DOI: 10.3233/CLO-2009-0497]
9. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805 [PMID: 18422971 DOI: 10.1111/j.1365-2559.2008.03028.x]
10. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33 [PMID: 20185938 DOI: 10.1159/000288295]
11. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18: 2833-2840 [PMID: 21468783 DOI: 10.1245/s10434-011-1695-2]
12. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379 [PMID: 16868827 DOI: 10.1007/s10620-005-9057-1]
13. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278 [PMID: 15668283 DOI: 10.1093/annonc/ mdi064]
14. Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a metaanalysis. Asian Pac J Cancer Prev 2011; 12: 1417-1423 [PMID: 22229170]
15. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
16. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51 [PMID: 17611206 DOI: 10.1056/NEJMra043186]
17. National Cancer Institute. Targeted Cancer Therapies (NCI Web site). Available from: URL: http: //www.cancer.gov/ cancertopics/factsheet/Therapy/targeted
18. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011; 58: 383-394 [PMID: 21323962 DOI: 10.1111/j.1365-2559.2011.03760.x]
19. Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000; 113: 852-859 [PMID: 10874886 DOI: 10.1309/VACP-VLQA-G9DX-VUDF]
20. Manion E, Hornick JL, Lester SC, Brock JE. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol 2011; 135: 845-851 [PMID: 21571957 DOI: 10.1309/AJCPIP5LOO3NGDJG]
21. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71 [PMID: 16328035]
22. Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, Kölble K, Kristiansen G. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007; 451: 19-25 [PMID: 17562074 DOI: 10.1007/s00428-007-0424-5]
23. Koh YW, Lee HJ, Lee JW, Kang J, Gong G. Dual-color silverenhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol 2011; 24: 794-800 [PMID: 21317877 DOI: 10.1038/modpathol.2011.9]
24. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, Dai D, Du W, Chen T, Chen M. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 2012; 62: 221-228 [PMID: 21927816 DOI: 10.1007/ s12013-011-9286-1]
25. Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 2007; 60: 1001-1005 [PMID: 17158643 DOI: 10.1136/jcp.2006.040287]
26. Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell' orto P, Veronesi P, Luini A, D'Alessandro C, Cardillo A, Goldhirsch A, Colleoni M. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007; 43: 2339-2344 [PMID: 17855075 DOI: 10.1016/j.ejca.2007.07.033]
27. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968; 70: 213-220 [PMID: 19673146]
28. Cho EY, Srivastava A, Park K, Kim J, Lee MH, Do I, Lee J, Kim KM, Sohn TS, Kang WK, Kim S. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 2012; 44: 216-220 [PMID: 22437741 DOI: 10.1097/PAT.0b013e3283513e8b]
29. Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res 2012; 14: R93 [PMID: 22694844 DOI: 10.1186/bcr3208]
30. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001; 14: 1079-1086 [PMID: 11706067 DOI: 10.1038/modpathol.3880440]
31. Drev P, Grazio SF, Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl Immunohistochem Mol Morphol 2008; 16: 179-184 [PMID: 18227723 DOI: 10.1097/PAI.0b013e31806875e1]
32. Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59: 822-831 [PMID: 22092393 DOI: 10.1111/ j.1365-2559.2011.04012.x]
33. Perrone G, Amato M, Callea M, Rabitti C, Righi D, Crucitti P, Coppola R, Onetti Muda A. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used? Histopathology 2012; 61: 134-135 [PMID: 22551459 DOI: 10.1111/ j.1365-2559.2012.04251.x]